Cargando…
An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
We conducted a phase I-IIa, randomized, monocentric, double-blind, placebo-controlled clinical trial to evaluate the safety and impact of the combination treatment of Itolizumab and insulin on preserving beta cell function in adults with recent-onset type 1 diabetes. Twelve patients were randomly as...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999981/ https://www.ncbi.nlm.nih.gov/pubmed/35407396 http://dx.doi.org/10.3390/jcm11071789 |
_version_ | 1784685321229697024 |
---|---|
author | Cabrera-Rode, Eduardo Cubas-Dueñas, Ileana Rodríguez-Acosta, Janet García-García, Yudith Torres-López, Yelena Prieto-Noa, Claudia Vázquez-Izada, Bárbara M. Ruíz-Reinoso, Maité Echevarría-Valdés, Ragmila Álvarez-Álvarez, Aimee Domínguez-Alonso, Emma Conesa-González, Ana Ibis González-Calero, Teresa Robles-Torres, Erick Turcios-Tristá, Silvia Elena Senra-Estévez, Elizabeth Hernández-Casaña, Patricia Sarmiento, Luis |
author_facet | Cabrera-Rode, Eduardo Cubas-Dueñas, Ileana Rodríguez-Acosta, Janet García-García, Yudith Torres-López, Yelena Prieto-Noa, Claudia Vázquez-Izada, Bárbara M. Ruíz-Reinoso, Maité Echevarría-Valdés, Ragmila Álvarez-Álvarez, Aimee Domínguez-Alonso, Emma Conesa-González, Ana Ibis González-Calero, Teresa Robles-Torres, Erick Turcios-Tristá, Silvia Elena Senra-Estévez, Elizabeth Hernández-Casaña, Patricia Sarmiento, Luis |
author_sort | Cabrera-Rode, Eduardo |
collection | PubMed |
description | We conducted a phase I-IIa, randomized, monocentric, double-blind, placebo-controlled clinical trial to evaluate the safety and impact of the combination treatment of Itolizumab and insulin on preserving beta cell function in adults with recent-onset type 1 diabetes. Twelve patients were randomly assigned to three treatment groups, each receiving a different Itolizumab dose (0.4/0.8/1.6 mg/kg body weight, respectively) and a placebo group. All patients received concomitant intensive multiple-dose insulin therapy. Endogenous insulin secretion was assessed by the measurement of C-peptide during the mixed-meal tolerance test. No serious adverse events were reported. No changes in the total daily insulin doses, glycated hemoglobin levels, and stimulated C-peptide were observed between the Itolizumab and placebo groups at 52 weeks. A significant decrease in stimulated C-peptide was observed during the follow-up period (p = 0.012). One subject treated with 1.6 mg of Itolizumab showed a marked increase in the levels of stimulated C-peptide three years after completion of the trial. Taken together, this is the first study to demonstrate that combination treatment with Itolizumab and insulin is safe in humans and does not affect the residual function of beta cells up to 52 weeks. The findings from our study show preliminary evidence that high doses of Itolizumab could potentially arrest the loss of beta cell function in the long term. Further studies with a longer follow-up and larger numbers of patients are envisaged to assess the effect with high dose Itolizumab. |
format | Online Article Text |
id | pubmed-8999981 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89999812022-04-12 An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes Cabrera-Rode, Eduardo Cubas-Dueñas, Ileana Rodríguez-Acosta, Janet García-García, Yudith Torres-López, Yelena Prieto-Noa, Claudia Vázquez-Izada, Bárbara M. Ruíz-Reinoso, Maité Echevarría-Valdés, Ragmila Álvarez-Álvarez, Aimee Domínguez-Alonso, Emma Conesa-González, Ana Ibis González-Calero, Teresa Robles-Torres, Erick Turcios-Tristá, Silvia Elena Senra-Estévez, Elizabeth Hernández-Casaña, Patricia Sarmiento, Luis J Clin Med Communication We conducted a phase I-IIa, randomized, monocentric, double-blind, placebo-controlled clinical trial to evaluate the safety and impact of the combination treatment of Itolizumab and insulin on preserving beta cell function in adults with recent-onset type 1 diabetes. Twelve patients were randomly assigned to three treatment groups, each receiving a different Itolizumab dose (0.4/0.8/1.6 mg/kg body weight, respectively) and a placebo group. All patients received concomitant intensive multiple-dose insulin therapy. Endogenous insulin secretion was assessed by the measurement of C-peptide during the mixed-meal tolerance test. No serious adverse events were reported. No changes in the total daily insulin doses, glycated hemoglobin levels, and stimulated C-peptide were observed between the Itolizumab and placebo groups at 52 weeks. A significant decrease in stimulated C-peptide was observed during the follow-up period (p = 0.012). One subject treated with 1.6 mg of Itolizumab showed a marked increase in the levels of stimulated C-peptide three years after completion of the trial. Taken together, this is the first study to demonstrate that combination treatment with Itolizumab and insulin is safe in humans and does not affect the residual function of beta cells up to 52 weeks. The findings from our study show preliminary evidence that high doses of Itolizumab could potentially arrest the loss of beta cell function in the long term. Further studies with a longer follow-up and larger numbers of patients are envisaged to assess the effect with high dose Itolizumab. MDPI 2022-03-24 /pmc/articles/PMC8999981/ /pubmed/35407396 http://dx.doi.org/10.3390/jcm11071789 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Cabrera-Rode, Eduardo Cubas-Dueñas, Ileana Rodríguez-Acosta, Janet García-García, Yudith Torres-López, Yelena Prieto-Noa, Claudia Vázquez-Izada, Bárbara M. Ruíz-Reinoso, Maité Echevarría-Valdés, Ragmila Álvarez-Álvarez, Aimee Domínguez-Alonso, Emma Conesa-González, Ana Ibis González-Calero, Teresa Robles-Torres, Erick Turcios-Tristá, Silvia Elena Senra-Estévez, Elizabeth Hernández-Casaña, Patricia Sarmiento, Luis An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes |
title | An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes |
title_full | An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes |
title_fullStr | An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes |
title_full_unstemmed | An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes |
title_short | An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes |
title_sort | exploratory study of itolizumab on the preservation of beta cell function in adults with recent-onset type 1 diabetes |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999981/ https://www.ncbi.nlm.nih.gov/pubmed/35407396 http://dx.doi.org/10.3390/jcm11071789 |
work_keys_str_mv | AT cabrerarodeeduardo anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT cubasduenasileana anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT rodriguezacostajanet anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT garciagarciayudith anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT torreslopezyelena anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT prietonoaclaudia anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT vazquezizadabarbaram anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT ruizreinosomaite anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT echevarriavaldesragmila anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT alvarezalvarezaimee anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT dominguezalonsoemma anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT conesagonzalezanaibis anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT gonzalezcaleroteresa anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT roblestorreserick anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT turciostristasilviaelena anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT senraestevezelizabeth anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT hernandezcasanapatricia anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT sarmientoluis anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT cabrerarodeeduardo exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT cubasduenasileana exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT rodriguezacostajanet exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT garciagarciayudith exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT torreslopezyelena exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT prietonoaclaudia exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT vazquezizadabarbaram exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT ruizreinosomaite exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT echevarriavaldesragmila exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT alvarezalvarezaimee exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT dominguezalonsoemma exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT conesagonzalezanaibis exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT gonzalezcaleroteresa exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT roblestorreserick exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT turciostristasilviaelena exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT senraestevezelizabeth exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT hernandezcasanapatricia exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes AT sarmientoluis exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes |